Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 5/20 | 0.45 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.40 |
| ▸ | SHBG | P04278 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | MBOAT4 | Q96T53 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9543830 | 0.88 | CYP19A1 (0.44) | CYP19A1SERPINA6SHBGALDH1A1SLC22A1 | |
| SCHEMBL3645097 | 0.83 | CYP19A1 (0.41) | CYP19A1SERPINA6SHBGALDH1A1SLC22A1 | |
| SCHEMBL7647438 | 0.81 | CYP19A1 (0.64) | CYP19A1SERPINA6SHBGALDH1A1LMNA | |
| SCHEMBL26425075 | 0.79 | CYP19A1 (0.66) | CYP19A1SERPINA6SHBGALDH1A1SLC22A1 | |
| SCHEMBL13216466 | 0.79 | CYP19A1 (0.66) | CYP19A1SERPINA6SHBGALDH1A1SLC22A1 | |
| SCHEMBL922877 | 0.79 | CYP19A1 (0.66) | CYP19A1SERPINA6SHBGALDH1A1SLC22A1 | |
| SCHEMBL19608861 | 0.79 | CYP19A1 (0.66) | CYP19A1SERPINA6SHBGALDH1A1SLC22A1 | |
| SCHEMBL11977689 | 0.79 | CYP19A1 (0.66) | CYP19A1SERPINA6SHBGALDH1A1SLC22A1 | |
| SCHEMBL6301566 | 0.78 | CYP19A1 (0.44) | CYP19A1SERPINA6SHBGALDH1A1SLC22A1 | |
| SCHEMBL3453459 | 0.78 | SERPINA6 (0.67) | CYP19A1SERPINA6SHBGALDH1A1SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207150-B2 | 17β-cyano-19-nor-androst-4-ene derivative, its use and medicaments comprising the derivative | Bayer Pharma AG (DE) | 2012-06-26 | — | — | US | disclosed |
| EP-1846434-B1 | NANDROLONE 17ß-CARBONATES | US GOV HEALTH & HUMAN SERV (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20090048217-A1 | 17Beta-CYANO-19-NOR-ANDROST-4-ENE DERIVATIVE, ITS USE AND MEDICAMENTS COMPRISING THE DERIVATIVE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-02-19 | — | — | US | disclosed |
| EP-1846434-A1 | NANDROLONE 17ß-CARBONATES | Government of the United States of America, Represented by the Secretary, Department of Health and Human Services (US) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006083618-A1 | NANDROLONE 17ß-CARBONATES | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048217-A1 | 17Beta-CYANO-19-NOR-ANDROST-4-ENE DERIVATIVE, ITS USE AND MEDICAMENTS COMPRISING THE DERIVATIVE | HSD17B11, HSD17B7, NR5A1 | CYP19A1 14/4885SERPINA6 860/4885SHBG 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.